Your browser doesn't support javascript.
loading
Dalotuzumab in chemorefractory KRAS exon 2 mutant colorectal cancer: Results from a randomised phase II/III trial.
Sclafani, Francesco; Kim, Tae Y; Cunningham, David; Kim, Tae W; Tabernero, Josep; Schmoll, Hans J; Roh, Jae K; Kim, Sun Y; Park, Young S; Guren, Tormod K; Hawkes, Eliza; Clarke, Stephen J; Ferry, David; Frodin, Jan-Erik; Ayers, Mark; Nebozhyn, Michael; Peckitt, Clare; Loboda, Andrey; Watkins, David J.
Afiliação
  • Sclafani F; The Royal Marsden NHS Foundation Trust, London and Surrey, United Kingdom.
  • Kim TY; Seoul National University College of Medicine, Seoul, Korea.
  • Cunningham D; The Royal Marsden NHS Foundation Trust, London and Surrey, United Kingdom.
  • Kim TW; Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.
  • Tabernero J; Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Schmoll HJ; Department of Internal Medicine, University Clinic Halle (Saale), Martin Luther University Halle-Wittenberg, Halle, Germany.
  • Roh JK; College of Medicine, Yonsey Cancer Center, Yonsey University, Seoul, Korea.
  • Kim SY; Center for Colorectal Cancer, National Cancer Center, Seoul, Korea.
  • Park YS; Department of Medicine, Division of Hematology/Oncology, Samsung Medical Center, Seoul, Korea.
  • Guren TK; Department of Oncology and K.G. Jebsen Colorectal Cancer Research Centre, Oslo University Hospital, Oslo, Norway.
  • Hawkes E; The Royal Marsden NHS Foundation Trust, London and Surrey, United Kingdom.
  • Clarke SJ; Concord Repatriation General Hospital, Concord, Sydney, Australia.
  • Ferry D; New Cross Hospital, Wolverhamptom, United Kingdom.
  • Frodin JE; Karolinska University Hospital, Stockholm, Sweden.
  • Ayers M; Merck & Co, Inc, Whitehouse Station, NJ.
  • Nebozhyn M; Merck & Co, Inc, Whitehouse Station, NJ.
  • Peckitt C; The Royal Marsden NHS Foundation Trust, London and Surrey, United Kingdom.
  • Loboda A; Merck & Co, Inc, Whitehouse Station, NJ.
  • Watkins DJ; The Royal Marsden NHS Foundation Trust, London and Surrey, United Kingdom.
Int J Cancer ; 140(2): 431-439, 2017 Jan 15.
Article em En | MEDLINE | ID: mdl-27681944
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Proteínas Proto-Oncogênicas p21(ras) / Anticorpos Monoclonais Humanizados / Anticorpos Monoclonais / Mutação Tipo de estudo: Clinical_trials Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Proteínas Proto-Oncogênicas p21(ras) / Anticorpos Monoclonais Humanizados / Anticorpos Monoclonais / Mutação Tipo de estudo: Clinical_trials Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article